A method of treating congenital cytomegalovirus (cCMV) induced hearing loss includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol.

A method of treating congenital cytomegalovirus (cCMV) induced hearing loss includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol.

A method of treating congenital cytomegalovirus (cCMV) induced hearing loss includes the step administering a composition to the mammal, wherein the composition consists essentially of a biologically effective amount of vitamin A, vitamin E, vitamin C, a vasodilator comprising magnesium, and, optionally, a withanolide, and/or resveratrol.

Compositions and methods for improving nitric oxide levels in a subject, comprising administering to a subject, a composition comprising dietary nitrate derived from potassium nitrate, beet root (whole plant, powder, plant extract), and/or nitrate-rich leafy green portions (whole plant, powder, plant extract) that improve functional nitric oxide levels in subjects as shown by increasing salivary bioconversion of nitrate to nitrite, a necessary a required step for nitric oxide mediated health benefits. The disclosed novel compositions improve cardiac health, lowers blood pressure, intraocular pressure, and LDL and restores nitric oxide mediated cardiovascular benefits, including but not limited, restoring endothelium function and improving flow mediated dilation.

Compositions and methods for improving nitric oxide levels in a subject, comprising administering to a subject, a composition comprising dietary nitrate derived from potassium nitrate, beet root (whole plant, powder, plant extract), and/or nitrate-rich leafy green portions (whole plant, powder, plant extract) that improve functional nitric oxide levels in subjects as shown by increasing salivary bioconversion of nitrate to nitrite, a necessary a required step for nitric oxide mediated health benefits. The disclosed novel compositions improve cardiac health, lowers blood pressure, intraocular pressure, and LDL and restores nitric oxide mediated cardiovascular benefits, including but not limited, restoring endothelium function and improving flow mediated dilation.

A 17β-estradiol/vitamin C molecular complex is obtained by compounding of 17β-estradiol and vitamin C in a molar ratio of 0.25:1, 0.5:1, 0.75:1, 1:1, 1:0.25, 1:0.5, or 1:0.75. A preparation method and use of the 17β-estradiol/vitamin C molecular complex are further provided. The 17β-estradiol/vitamin C molecular complex can be distributed to a bone tissue in a bone-targeted manner, which not only significantly improves the anti-osteoporosis activity of 17β-estradiol but also effectively prevents the side effects of endometrial hyperplasia and thrombosis caused by treatment with 17β-estradiol and conjugated estrogens.

A 17β-estradiol/vitamin C molecular complex is obtained by compounding of 17β-estradiol and vitamin C in a molar ratio of 0.25:1, 0.5:1, 0.75:1, 1:1, 1:0.25, 1:0.5, or 1:0.75. A preparation method and use of the 17β-estradiol/vitamin C molecular complex are further provided. The 17β-estradiol/vitamin C molecular complex can be distributed to a bone tissue in a bone-targeted manner, which not only significantly improves the anti-osteoporosis activity of 17β-estradiol but also effectively prevents the side effects of endometrial hyperplasia and thrombosis caused by treatment with 17β-estradiol and conjugated estrogens.

A 17β-estradiol/vitamin C molecular complex is obtained by compounding of 17β-estradiol and vitamin C in a molar ratio of 0.25:1, 0.5:1, 0.75:1, 1:1, 1:0.25, 1:0.5, or 1:0.75. A preparation method and use of the 17β-estradiol/vitamin C molecular complex are further provided. The 17β-estradiol/vitamin C molecular complex can be distributed to a bone tissue in a bone-targeted manner, which not only significantly improves the anti-osteoporosis activity of 17β-estradiol but also effectively prevents the side effects of endometrial hyperplasia and thrombosis caused by treatment with 17β-estradiol and conjugated estrogens.

The present patent application relates a process for the production of compressed tablets using specific coated particles, wherein the coating (system) comprises at least one wax and/or at least one fat. Furthermore it relates to compressed (compacted) tablets and as well as to specific coated particles.

The present patent application relates a process for the production of compressed tablets using specific coated particles, wherein the coating (system) comprises at least one wax and/or at least one fat. Furthermore it relates to compressed (compacted) tablets and as well as to specific coated particles.